Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saizen Dosage Optimization in SGA Children
NCT00249821Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2005
- Primary completion
- Sep 2007
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
01
Overview
Phase 3, randomised, open-label trial of somatropin in Small for gestational age (SGA) (2 arms), sponsored by Merck KGaA. Primary endpoint: Height Velocity at 12 months. Started Feb 2005; status: completed.
02
Drugs
somatropin
03
Conditions
Small for gestational age (SGA)
Beyond the preview
Go deeper on NCT00249821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249821.